EP3866768A4 - Use of reboxetine to treat narcolepsy - Google Patents
Use of reboxetine to treat narcolepsy Download PDFInfo
- Publication number
- EP3866768A4 EP3866768A4 EP19874099.5A EP19874099A EP3866768A4 EP 3866768 A4 EP3866768 A4 EP 3866768A4 EP 19874099 A EP19874099 A EP 19874099A EP 3866768 A4 EP3866768 A4 EP 3866768A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reboxetine
- treat narcolepsy
- narcolepsy
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745956P | 2018-10-15 | 2018-10-15 | |
PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3866768A1 EP3866768A1 (en) | 2021-08-25 |
EP3866768A4 true EP3866768A4 (en) | 2022-01-05 |
Family
ID=70284075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19874099.5A Pending EP3866768A4 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3866768A4 (en) |
JP (1) | JP2022504975A (en) |
KR (1) | KR20210071046A (en) |
CN (1) | CN112888430A (en) |
AU (2) | AU2019361915A1 (en) |
BR (1) | BR112021007019A2 (en) |
CA (1) | CA3115983A1 (en) |
CL (1) | CL2021000924A1 (en) |
CO (1) | CO2021004681A2 (en) |
CR (1) | CR20210514A (en) |
EC (1) | ECSP21031200A (en) |
IL (1) | IL282311A (en) |
MX (1) | MX2021004207A (en) |
PE (1) | PE20211199A1 (en) |
SG (1) | SG11202103588WA (en) |
WO (1) | WO2020081461A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
KR20230055668A (en) * | 2021-10-19 | 2023-04-26 | 단국대학교 천안캠퍼스 산학협력단 | Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
US20080261984A1 (en) * | 2004-06-09 | 2008-10-23 | Pfizer Inc. | Use of S,S-Reboxetine in the Treatment of Pain |
HUE060060T2 (en) * | 2013-03-13 | 2023-01-28 | Jazz Pharmaceuticals Ireland Ltd | Treatment of cataplexy |
-
2019
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/en unknown
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/en not_active IP Right Cessation
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/en active Pending
- 2019-10-14 CR CR20210514A patent/CR20210514A/en unknown
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en unknown
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/en unknown
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/en unknown
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/en active Pending
- 2019-10-14 CA CA3115983A patent/CA3115983A1/en active Pending
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
-
2021
- 2021-04-13 IL IL282311A patent/IL282311A/en unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/en unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/en unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/en unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en active Pending
Non-Patent Citations (3)
Title |
---|
GARCIA-BORREGUERO D ET AL: "Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP (ROCHESTER), vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), & 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, pages A323 - A324, XP009531711, ISSN: 0161-8105 * |
O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024 * |
SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020081461A1 (en) | 2020-04-23 |
CL2021000924A1 (en) | 2021-09-03 |
PE20211199A1 (en) | 2021-07-01 |
CR20210514A (en) | 2021-11-12 |
MX2021004207A (en) | 2021-08-11 |
EP3866768A1 (en) | 2021-08-25 |
CA3115983A1 (en) | 2020-04-23 |
AU2023200917A1 (en) | 2023-03-23 |
IL282311A (en) | 2021-05-31 |
JP2022504975A (en) | 2022-01-13 |
CO2021004681A2 (en) | 2021-06-21 |
SG11202103588WA (en) | 2021-05-28 |
ECSP21031200A (en) | 2021-05-31 |
BR112021007019A2 (en) | 2021-07-13 |
CN112888430A (en) | 2021-06-01 |
KR20210071046A (en) | 2021-06-15 |
AU2019361915A1 (en) | 2021-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3612551A4 (en) | Variants of cpf1 (cas12a) with altered pam specificity | |
EP3313404A4 (en) | Therapeutic compositions, combinations, and methods of use | |
EP3426250A4 (en) | Methods of treatment | |
EP3294289A4 (en) | Use of cannabis to treat fibromyalgia, methods and compositions thereof | |
EP3256113A4 (en) | Treatment of hypoparathyroidism | |
GB201804514D0 (en) | Treatment of pyroptosis | |
IL282311A (en) | Use of reboxetine to treat narcolepsy | |
EP3370726A4 (en) | Use of tlr8 agonists to treat cancer | |
EP3536320A4 (en) | Application of hedgehog pathway inhibitor for treatment of fibrotic diseases | |
EP3359258A4 (en) | Compositions and methods of treating skin fibrotic disorders | |
EP3902524A4 (en) | Treatment of skin disorders with compositions comprising an egfr inhibitor | |
EP3833372A4 (en) | Treatment of egfr-mutant cancer | |
EP3675871A4 (en) | Compositions and methods for the treatment of fibrotic diseases | |
EP3735209A4 (en) | Treatment of myopic progression | |
EP3752466A4 (en) | Treatment of cyanotoxin-containing water | |
EP3661507A4 (en) | Use of gaboxadol in the treatment of narcolepsy | |
GB201804515D0 (en) | Treatment of necroptosis | |
EP3829619A4 (en) | Treatment of mucopolysaccharidosis iva | |
EP3600285A4 (en) | Topical compositions and methods of treatment | |
EP3976085A4 (en) | Use of prg4 to treat cancer | |
EP3721889A4 (en) | Use of butyribacter intestini | |
EP3878454A4 (en) | Use of 3-o-sulfamate-16,16-dimethyl-d-homoequilenin to treat oncological diseases | |
IL285119A (en) | Use of spiropidion | |
EP3384285A4 (en) | Treatment of fibrotic conditions | |
IL282869A (en) | Use of tivozanib to treat subjects with refractory cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210506 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20211207 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20211201BHEP Ipc: A61K 31/5375 20060101ALI20211201BHEP Ipc: A61K 9/22 20060101AFI20211201BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060016 Country of ref document: HK |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230927 |